Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018

Simple item page
dc.contributor.authorDu Toit, Tessaen_ZA
dc.contributor.authorEsterhuizen, Tonya M.en_ZA
dc.contributor.authorTiffin, Nickien_ZA
dc.contributor.authorAbulfathi, Ahmed A.en_ZA
dc.contributor.authorReuter, Helmuthen_ZA
dc.contributor.authorDecloedt, Eric H.en_ZA
dc.date.accessioned2021-03-04T13:52:14Z
dc.date.available2021-03-04T13:52:14Z
dc.date.issued2019
dc.descriptionCITATION: Du Toit, T., 2019. Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018. BMC Infectious Diseases, 20:900, doi:10.1186/s12879-020-05624-0.
dc.descriptionThe original publication is available at https://bmcinfectdis.biomedcentral.com
dc.description.abstractBackground: South Africa has one of the highest tuberculosis incidence rates. Biologic disease-modifying antirheumatic drugs are associated with an increased risk of tuberculosis. The objective of this study was to describe the tuberculosis disease incidence rate among public sector patients receiving biologic therapies in the Western Cape Province. Methods: A retrospective, descriptive analysis was undertaken using routine health data collated by the Provincial Health Data Centre from January 2007 (first use of biologic therapy in the Western Cape) to September 2018. Results: We identified 609 patients treated with tumour necrosis factor-alpha (TNF-α) or non-TNF-α biologic therapies. Thirty-seven (37) patients developed tuberculosis after biologic therapy exposure, of whom the majority (78%) had an immune mediated inflammatory disease and the remainder (22%) a haematologic malignancy. The incidence rate of tuberculosis per 100,000 person-years was 2227 overall [95% confidence interval (CI): 1591, 3037]. Patients treated with TNF-α inhibitors and non-TNF-α inhibitors had estimated incidence rates of 2819 [95% CI: 1669, 4480] and 1825 [95% CI: 1131, 2797], respectively (p = 0.10). Conclusion: Patients exposed to both TNF-α and non-TNF-α biologic therapies may have a higher incidence of tuberculosis disease compared to the background risk of 681 cases per 100,000 per year in the Western Cape.en_ZA
dc.description.urihttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05624-0
dc.description.versionPublisher's version
dc.format.extent8 pagesen_ZA
dc.identifier.citationDu Toit, T., 2019. Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018. BMC Infectious Diseases, 20:900, doi:10.1186/s12879-020-05624-0
dc.identifier.issn1471-2334 (online)
dc.identifier.otherdoi:10.1186/s12879-020-05624-0
dc.identifier.urihttp://hdl.handle.net/10019.1/109623
dc.language.isoen_ZAen_ZA
dc.publisherBMC (part of Springer Nature)en_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectTuberculosisen_ZA
dc.subjectNecrosisen_ZA
dc.subjectTumorsen_ZA
dc.subjectBiologicalsen_ZA
dc.titleIncident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018en_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
dutoit_incident_2019.pdf
Size:
681.69 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Clinical Pharmacology)